CUSIP Global Services (CGS) today announced the release of its CUSIP Issuance Trends Report for October 2025. The report, ...

Chad Langager is a co-founder of Second Summit Ventures. He started as an intern at Investopedia.com, eventually leaving for the startup scene. Samantha (Sam) Silberstein, CFP®, CSLP®, EA, is an ...

A CUSIP is a number assigned to a registered security such as a stock, bond, or mutual fund so that the security can be uniquely identified. The Committee on Uniform Securities Identification ...

The Federal Deposit Insurance Corporation board shocked the municipal bond market on Tuesday with a proposal that would switch out CUSIP numbers with Financial Instrument Global Identifiers, a marker ...

Adam Hayes, Ph.D., CFA, is a financial writer with 15+ years Wall Street experience as a derivatives trader. Besides his extensive derivative trading expertise, Adam is an expert in economics and ...

The Securities and Exchange Commission has approved the Municipal Securities Rulemaking Board's proposed changes to its Rule G-34 on CUSIP numbers, which both issuers and muni advisors said will ...

Moleculin Biotech Inc. (NASDAQ:MBRX) saw its shares tumble 20.6% in premarket trading on Wednesday after unveiling plans for ...

CUSIP numbers uniquely identify North American securities, facilitating faster trading. CUSIP numbers, started in 1964 due to trade clearance delays, are integral to U.S. securities. CUSIP identifiers ...

FactSet ended its year with a bang—for its buck, that is. On December 27, the financial data provider announced that it would acquire Cusip Global Services (CGS), the operator of the Cusip reference ...

REX Shares and Tuttle Capital Management ("T-REX") today announced the execution of a reverse share split for the following exchange-traded fund ("Fund"): ...

Data licenses from Cusip Global Services (CGS)—and the things they do and do not permit—sit at the heart of an ongoing federal court case in the Southern District of New York. Recent witness testimony ...

NEW YORK--(BUSINESS WIRE)--OS Therapies (NYSE American: OSTX) (“OS Therapies” or “the Company”), an ADC and Immunotherapy research and clinical-stage biopharmaceutical company, today provided a ...